The FDA yesterday approved Revolution Medicines' Rasonque (daraxonrasib) for second-line-plus metastatic pancreatic adenocarcinoma, based on RASolute 302 data showing a 60% reduction in risk of death (median OS 13.2 vs 6.7 months) versus chemotherapy — a landmark result that cements RAS(ON) inhibition as the emerging standard of care in pancreatic cancer. The approval process just took one month.
LÄS MER
